How Methotrexate Causes Kidney Damage
Methotrexate, a folate antagonist used in chemotherapy and autoimmune diseases, impairs renal function primarily through precipitation of its metabolites in kidney tubules. High-dose methotrexate (typically >500 mg/m²) produces 7-hydroxymethotrexate, which is poorly soluble at urinary pH levels below 7. This leads to crystal formation in the distal tubules and collecting ducts, causing acute kidney injury via tubular obstruction and inflammation.[1][2]
Key Mechanism: Reduced Solubility and Tubular Precipitation
At acidic urine pH (<7), methotrexate and its metabolite 7-OH-MTX have low solubility (<1 mmol/L), forming needle-shaped crystals that block urine flow. This raises intratubular pressure, reduces glomerular filtration rate (GFR), and triggers direct tubular toxicity from oxidative stress and inflammation. Studies show urine MTX levels >1 mmol/L correlate strongly with nephrotoxicity.[1][3]
Risk Factors That Worsen Impact
- High doses and prolonged exposure: Common in cancer regimens; risk jumps above 1 g/m² without hydration.[2]
- Pre-existing conditions: Dehydration, low urine pH (from acidosis or drugs like salicylates), renal impairment, or third-space fluid shifts (e.g., ascites) delay clearance.[1][4]
- Drug interactions: NSAIDs, proton pump inhibitors, or antibiotics like trimethoprim compete for secretion via organic anion transporters (OAT1/3), elevating plasma levels.[3]
Older age and hypoalbuminemia amplify risks by reducing protein binding and clearance.[2]
Monitoring and Prevention Strategies
Hydration (2-3 L/m²/day) and urinary alkalinization (pH >7 with sodium bicarbonate) increase solubility 10-100 fold, preventing precipitation. Leucovorin rescue doesn't help kidneys but protects bone marrow. Serum MTX levels guide glucarpidase use if >10 µmol/L at 24 hours post-dose. Baseline creatinine clearance <60 mL/min contraindicates high-dose use.[1][4]
Clinical Outcomes and Recovery
Nephrotoxicity occurs in 5-20% of high-dose cases without prophylaxis, with creatinine rising 1.5-10x baseline within 48 hours. Most recover fully with intervention, but 1-5% progress to dialysis-requiring acute tubular necrosis. Low-dose oral use (e.g., rheumatoid arthritis) rarely affects kidneys unless dehydrated.[2][3]
Sources
[1]: DrugPatentWatch.com - Methotrexate Patent Insights (summarizes pharmacology)
[2]: NEJM - High-Dose Methotrexate Nephrotoxicity
[3]: Clinical Pharmacology & Therapeutics - MTX Pharmacokinetics
[4]: ASCO Guidelines - MTX Monitoring